Mifepristone: bioavailability, pharmacokinetics and use-effectiveness

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 101, Issue 2, 2002, Pages 113-120

  Sarkar, N N ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Abortifacient; Anti progestin; Contraceptive; Progesterone; Receptor; RU486; Steroid

Indexed keywords

MIFEPRISTONE;

ABORTION; BIOAVAILABILITY; CONTRACEPTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INFORMATION; DRUG MECHANISM; DRUG METABOLISM; OVULATION; PREGNANCY; PRIORITY JOURNAL; REVIEW; SEXUAL INTERCOURSE;

EID: 0037051129     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(01)00522-X     Document Type: Review

References (69)

1. Effect d'um steroide antiprogesterone chez la femme: interruption dy cucle menstruel et dela grossese an bedut
2. Clinical pharmacology of RU486: an anti-progestin and anti-glucocorticoid
3. Mifepristone and first trimester abortion
4. Mifepristone: clinical pharmacolgy
5. Pharmocokinetic study of RU486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women
6. Plasma levels of anti progestin RU486 following oral administration to non-pregnant and early pregnant women
7. Pharmacokinetics of antiprogesterone RU486 in women after oral administration
8. Pharmacokinetics of the antiprogestin RU486 in women during multiple doses administration
9. Quantitation of RU486 in human plasma by HPLC and RIA after column chromatography
10. Determination of RU486 (mifepristone) in blood by radioreceptor assay: a pharmacokinetic study
11. Antiprogestational steroids: a new dimension in fertility regulation
12. Mifepristone: antineoplastic studies
13. Distribution of RU486 and its demethylated metabolites in human
14. Plasma concentrations and receptor binding of RU486 and its metabolites in human
15. Effect of continuous treatment with low dose mifepristone throughout one menstrual cycle
16. Pharmacokinetics of mifepristone after low oral doses
17. Dose response relationship of RU486
18. Phrmacokinetic study of orally administered RU486 in non-pregnant women
19. Pharmacokinetics of RU486 and its active metabolites in humans
20. Levels of antiprogestin RU486 and its metabolites in human blood and follicular fluid following oral administration of a single dose
21. Clinical pharmacokinetics of mifepristone
22. Progesterone receptors: expression and regulation in the mammalian ovary
23. Atomic structure of progesterone complexed with its receptors
24. Molecular mechanism of action of steroid/thyroid receptor super family members
25. Dimerization of mammalian progesterone receptors occurs in the absence of DNA and is related to the release of the 90-kDa heat shock protein
26. Effects of the steroid antagonist RU486 on dimerization of the human progesterone receptor
27. A single amino acid that determines the sensitivity of progesterone receptors to RU486
28. RU486: the French experience
29. The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy less than 63 days gestation: UK multicentre study-final results
30. Termination of early pregnancy by two regimens of mifepristone with misoprostol and mifepristone with PGO5: a multicentre clinical trial in China
31. Termination of early human pregnancy with either 50 or 200 mg single oral dose of mifepristone (RU486) in combination with either 0.5 mg or 1 mg vaginal gemeprost
32. Safety efficacy and acceptability of medical abortion in China Cuba and India. A comparative trial of mifepristone-misoprostol versus surgical abortion
33. Mifepristone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential
34. Blood loss in termination of early pregnancy with mifepristone and gemeprost
35. Blood loss with mifepristone-misoprostol abortion; measures from a trial in China, Cuba and India
36. Side effects of mifepristone-misoprostol abortion versus surgical abortion. Data from a trial in China, Cuba and India
37. Outcome of suction curettage and mifepristone abortion in the United States. A prospective comparison study
38. Early pregnancy ternnnation with mifepristone and misoprostol in the United States
39. Interruption of early pregnancy with mifepristone in combination with gemeprost
40. An effective regimen for early medical abortion: report of 2000 consecutive cases
41. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion
42. Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days
43. A comparison of the abortion rights mobilization and population council trials
44. Research on regimens for early nedical abortion
45. The efficacy of medical abortion: a meta-analysis
46. Misoprostol for medical evacuation of early pregnancy failure
47. Comparison between oral and vaginal administration of misoprostol on uterine contractility
48. Absorption kinetics of misoprostol with oral or vaginal administration
49. Phmmacokinetics of antiprogesterone RU486; no correlation to clinical perforrnance of RU486
50. Contragestion and other clinical applications of RU486, an anti-progesterone at the receptor
51. Mifepristrone (RU486) compared with high-dose estrogen and progestogen for emergency post-coital contraception
52. Comparison of Yuzpe regimen, danazol and mifepristone (RU486) in oral post-coital contraception
53. Hormonal anti-implantation agents, anti progestins
54. Contraception with anti-progesterone
55. Emergency contraception with mifepristone and anordin
56. Effect of low weekly doses of mifepristone on ovarian function and endometrial development
57. Effect of low daily doses of mifepristone on ovarian function and endometrial development
58. Antinidatory effect of luteal phase administration of mifepristone (RU486) is associated with changes in endometrial prostaglandins during implantation window
59. The possible use of anti-progestins for contraception
60. Effect of once weekly administration of mifepristone on ovarian function in normal women
61. Effect of long-term low-dose mifepristone on reproductive function in women
62. Contraceptive efficacy of low doses of mifepristone
63. Early luteal phase treatment with mifepristone (RU486) for fertility regulation
64. Comparative use of anti-progestin
65. Mifepristone as abortifacient and contraceptive drug: attitude, efficacy and acceptability